[go: up one dir, main page]

PL1673107T3 - Kompozycja farmaceutyczna zawierająca selektywnego agonistę receptora imidazoliny I1 i bloker receptora angiotensyny II - Google Patents

Kompozycja farmaceutyczna zawierająca selektywnego agonistę receptora imidazoliny I1 i bloker receptora angiotensyny II

Info

Publication number
PL1673107T3
PL1673107T3 PL04766880T PL04766880T PL1673107T3 PL 1673107 T3 PL1673107 T3 PL 1673107T3 PL 04766880 T PL04766880 T PL 04766880T PL 04766880 T PL04766880 T PL 04766880T PL 1673107 T3 PL1673107 T3 PL 1673107T3
Authority
PL
Poland
Prior art keywords
angiotensin
selective
pharmaceutical composition
receptor
imidazoline
Prior art date
Application number
PL04766880T
Other languages
English (en)
Inventor
Dominique Baum
Gerhard-Wilhelm Bielenberg
Bernd Boedecker
Dirk Thormaehlen
Original Assignee
Abbott Laboratories Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories Gmbh filed Critical Abbott Laboratories Gmbh
Publication of PL1673107T3 publication Critical patent/PL1673107T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL04766880T 2003-10-10 2004-10-07 Kompozycja farmaceutyczna zawierająca selektywnego agonistę receptora imidazoliny I1 i bloker receptora angiotensyny II PL1673107T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03103763 2003-10-10
PCT/EP2004/052468 WO2005039639A2 (en) 2003-10-10 2004-10-07 Pharmaceutical composition comprising a selective i1 imidazoline receptor agonist and an angiotensin ii receptor blocker
EP04766880A EP1673107B1 (en) 2003-10-10 2004-10-07 Pharmaceutical composition comprising a selective i1 imidazoline receptor agonist and an angiotensin ii receptor blocker

Publications (1)

Publication Number Publication Date
PL1673107T3 true PL1673107T3 (pl) 2008-06-30

Family

ID=34486329

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04766880T PL1673107T3 (pl) 2003-10-10 2004-10-07 Kompozycja farmaceutyczna zawierająca selektywnego agonistę receptora imidazoliny I1 i bloker receptora angiotensyny II

Country Status (19)

Country Link
US (2) US20050143435A1 (pl)
EP (1) EP1673107B1 (pl)
JP (1) JP4829115B2 (pl)
KR (1) KR101137084B1 (pl)
CN (1) CN100453117C (pl)
AT (1) ATE390148T1 (pl)
AU (1) AU2004283047B2 (pl)
BR (1) BRPI0415198A (pl)
CA (1) CA2541867C (pl)
DE (1) DE602004012763T2 (pl)
ES (1) ES2304624T3 (pl)
IL (1) IL174762A (pl)
MX (1) MXPA06004029A (pl)
NO (1) NO335735B1 (pl)
PL (1) PL1673107T3 (pl)
RU (1) RU2362561C2 (pl)
UA (1) UA83077C2 (pl)
WO (1) WO2005039639A2 (pl)
ZA (1) ZA200601804B (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4675586B2 (ja) * 2004-06-23 2011-04-27 壽製薬株式会社 高血圧症及び血清高尿酸血症の重複発症の治療のための薬剤
AU2006306420A1 (en) * 2005-10-25 2007-05-03 Merck Sharp & Dohme Corp. Combination of a dipeptidyl peptidase-4 inhibitor and an anti-hypertensive agent for the treatment of diabetes and hypertension
EP2269583B1 (en) 2006-06-16 2014-08-13 LEK Pharmaceuticals d.d. Pharmaceutical composition comprising hydrochlorothiazide and telmisartan
EP2018885B1 (en) 2007-07-25 2011-02-09 Schott forma vitrum ag Application device
EP2203158A4 (en) * 2007-10-30 2012-12-26 Reddys Lab Ltd Dr PHARMACEUTICAL FORMULATIONS WITH TELMISARTAN AND HYDROCHLORTHIAZIDE
US9173848B2 (en) * 2009-06-30 2015-11-03 Sanofi Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application
CN102850331B (zh) * 2012-09-17 2015-05-20 符爱清 一种化合物的制备方法
MD4412C1 (ro) * 2014-08-29 2016-11-30 Алёна ДУРНЯ Utilizare a acidului 4-({2-butil-5-[2-carboxi-2-(tiofen-2-ilmetil)et-1-en-1-il] -1H-imidazol-1-il}metil) benzoic pentru ameliorarea elasticităţii vasculare în profilaxia complicaţiilor de geneză hipertensivă
PL424452A1 (pl) * 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu
RU2734281C1 (ru) * 2019-06-11 2020-10-14 Федеральное государственное бюджетное учреждение науки Институт теоретической и экспериментальной биофизики Российской академии наук (ИТЭБ РАН) Композиция для лечения артериальной гипертензии и ассоциированных с ней патологий сердечно-сосудистой системы
EP3986412A4 (en) 2019-06-21 2023-11-15 The Broad Institute, Inc. AGENTS TO REVERSE TOXIC PROTEINOPATHIES
GB202006074D0 (en) * 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
WO2025002914A1 (en) 2023-06-26 2025-01-02 Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (F.S.P.) Antagonists of the imidazoline-1 receptor for use in the prevention and/or treatment of an autoinflammatory or autoimmune disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
US5354867A (en) * 1988-12-06 1994-10-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
US5312828A (en) * 1989-06-14 1994-05-17 Finkelstein Joseph A Substituted imidazoles having angiotensin II receptor blocking activity
DE122010000024I1 (de) * 1990-02-19 2010-07-08 Novartis Ag Acylverbindungen
US5270317A (en) * 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
JP2707390B2 (ja) * 1992-05-22 1998-01-28 壽製薬株式会社 シクロヘプトイミダゾ−ル誘導体及びその製造方法並びにこれを含有する薬剤
DE4423177A1 (de) * 1994-07-01 1996-01-04 Kali Chemie Pharma Gmbh Antihyperglykämisch wirksame Arzneimittel
US5972948A (en) * 1994-07-01 1999-10-26 Solvay Pharmaceuticals Gmbh Method of inhibiting hyperglycemia and pharmaceutical composition for use therein
CA2229123A1 (en) * 1997-02-11 1998-08-11 Mitchell Irvin Steinberg Pharmaceutical agents
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
JP4107831B2 (ja) * 2000-11-21 2008-06-25 第一三共株式会社 医薬組成物
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
HU0200980D0 (pl) * 2002-03-14 2002-05-29 Gabor S Pal Dr
WO2004024720A1 (en) * 2002-09-11 2004-03-25 Merck & Co., Inc. Piperazine urea derivatives as melanocortin-4 receptor agonists

Also Published As

Publication number Publication date
JP2007508276A (ja) 2007-04-05
JP4829115B2 (ja) 2011-12-07
IL174762A0 (en) 2006-08-20
ATE390148T1 (de) 2008-04-15
CN100453117C (zh) 2009-01-21
ES2304624T3 (es) 2008-10-16
CA2541867C (en) 2012-06-12
NO335735B1 (no) 2015-02-02
AU2004283047B2 (en) 2009-09-17
WO2005039639A3 (en) 2005-08-11
KR101137084B1 (ko) 2012-04-24
MXPA06004029A (es) 2006-06-28
KR20060117912A (ko) 2006-11-17
US20110229571A1 (en) 2011-09-22
RU2006115796A (ru) 2007-11-27
DE602004012763D1 (de) 2008-05-08
EP1673107B1 (en) 2008-03-26
NO20062088L (no) 2006-07-07
BRPI0415198A (pt) 2006-12-05
IL174762A (en) 2010-11-30
HK1096293A1 (zh) 2007-06-01
UA83077C2 (ru) 2008-06-10
US20050143435A1 (en) 2005-06-30
CN1859924A (zh) 2006-11-08
CA2541867A1 (en) 2005-05-06
EP1673107A2 (en) 2006-06-28
WO2005039639B1 (en) 2005-09-22
WO2005039639A2 (en) 2005-05-06
RU2362561C2 (ru) 2009-07-27
DE602004012763T2 (de) 2009-05-07
ZA200601804B (en) 2007-05-30
AU2004283047A1 (en) 2005-05-06

Similar Documents

Publication Publication Date Title
UA96308C2 (ru) Антагонисты рецептора глюкагона, композиция, которая содержит такие соединения, и их применение
IL174762A0 (en) Pharmaceutical composition comprising a selective i1 imidazoline receptor agonist and an angiotensin ii receptor blocker
TW200605882A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
TW200607798A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
ATE468853T1 (de) Substituierte pyrazole, derartige verbindungen enthaltende zusammensetzungen und verfahren zu ihrer verwendung
TW200730202A (en) Solid dosage form
WO2008021851A3 (en) Novel compounds as antagonists or inverse agonists for opioid receptors
WO2004100875A3 (en) Benzimidazoles, compositions containing such compounds and methods of use
ATE469895T1 (de) Cgrp-rezeptorantagonisten
GR20040100121A (el) Συνθεσεις περιεχουσες αγωνιστη υποδοχεων s1p
MXPA06011924A (es) Dispositivo de liberacion continua base polimeros.
MY162095A (en) Method of treating symptoms of hormonal variations
DK2049475T3 (da) Cyclohexyl-substituerede pyrrolidinoner som inhibitorer af 11-beta-hydroxysteroid dehydrogenase1
MX2007009389A (es) Agonistas de pyy y sus usos.
WO2009050136A3 (en) Glucocorticoid receptor antagonists such as mifepristone for treating cushing' s syndrome
TW200745031A (en) Acyl indoles, compositions containing such compounds and methods of use
EP1549655A4 (en) SUBSTITUTED BICYCLIC THIOPHENE DERIVATIVES, COMPOSITIONS AND METHOD OF ADMINISTRATION CONTAINING SUCH COMPOUNDS
EA200801369A1 (ru) Способы трансдермального введения агониста рецептора индолсеротонина и трансдермальные лекарственные формы для применения этого способа
UA98472C2 (ru) Применение агониста рецептора epo человека для лечения интолерантности к глюкозе
TW200501953A (en) Combination therapy for hypertension using lercanidipine and an angiotensin II receptor blocker
MX2008000874A (es) Metodos y composiciones para anticoncepcion de emergencia utilizando antagonistas del receptor de endotelina.
GB0111220D0 (en) Restricting reinstatement of drug use
MX2007004461A (es) Composiciones farmaceuticas a base de antagonistas de nk2 para uso pediatrico.
WO2007024752A3 (en) Methods and compositions for the treatment and diagnosis of endothelial cell disorders and angiogenic disorders
DK1420789T3 (da) Anvendelse af aktivstoffer med my-opioid-receptoragonistisk virkning og opioid-receptorantagonistisk virkning som kombinationslægemidler til cancerbehandling